Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Waldenstrom's Macroglobulinemia
NCT00045695Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2002
- Primary completion
- Mar 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Waldenstrom macroglobulinemia (WM), sponsored by Canadian Cancer Trials Group. Primary endpoint: Response Rate at 4 years. Started Aug 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00045695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045695.